Tirzepatide (Tirz) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed for advanced research into metabolic disorders, obesity, and glucose regulation. By activating both incretin pathways, Tirzepatide enhances insulin secretion, improves insulin sensitivity, and reduces appetite, making it a promising subject in preclinical metabolic and weight management studies.

Research Applications & Potential Effects:

• Research on blood glucose regulation and insulin resistance reduction

• Studies into appetite suppression and caloric intake reduction

• Evaluation of dual incretin synergy for weight control

• Preclinical investigations into cardiovascular and lipid health markers

Supplied as a sterile, lyophilised powder to ensure maximum purity and stability for accurate experimental results.

Molecular Formula: C225H348N48O68
Molar Mass: 4813.52 g/mol
Form: Lyophilised powder
Purity: ≥ 99% (HPLC)
Storage: Store at −20 °C, protect from light
Intended Use: Strictly for research purposes only. Not for human consumption, medical, or veterinary use.
CAS Number: 2023788-19-2